Alkermes plc logo

ALKS

Alkermes plc

$24.2

Earnings Summary

Revenue
$265.01Mn
Net Profits
$-0.13Mn
Net Profit Margins
-0.05%

Highlights

Revenue:

Alkermes plc’s revenue jumped 3.83% since last year same period to $265.01Mn in the Q3 2020. On a quarterly growth basis, Alkermes plc has generated 7.06% jump in its revenue since last 3-months.

Net Profits:

Alkermes plc’s net profit jumped 99.75% since last year same period to $-0.13Mn in the Q3 2020. On a quarterly growth basis, Alkermes plc has generated 99.54% jump in its net profits since last 3-months.

Net Profit Margins:

Alkermes plc’s net profit margin jumped 99.76% since last year same period to -0.05% in the Q3 2020. On a quarterly growth basis, Alkermes plc has generated 99.57% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Alkermes plc post its latest quarter earnings

EPS Estimate Current Quarter
-0.01
EPS Estimate Current Year
-0.01

Highlights

EPS Estimate Current Quarter:

Alkermes plc’s earning per share (EPS) estimates for the current quarter stand at -0.01 - a -115.62% fall from last quarter’s estimates.

EPS Estimate Current Year:

Alkermes plc’s earning per share (EPS) estimates for the current year stand at -0.01.

Key Ratios

Key ratios of the Alkermes plc post its Q4 2022 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

Alkermes plc’s earning per share (EPS) fell -100% since last year same period to 0 in the Q4 2022. This indicates that the Alkermes plc has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-04-27
0.03
0.12
380%
2022-07-27
0.01
0.06
745.07%
2023-02-15
-0.01
0
100%
2022-11-02
0.03
0
-100%

Company Information

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.

Organisation
Alkermes plc
Headquarters
Connaught House, Dublin, Ireland, 4
Employees
2211
Industry
Health Technology
CEO
Richard F. Pops

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*